secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0001104659-23-062121
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode receives Nasdaq delisting notice for negative stockholders' equity of $(236,792) as of Q1
--------------------------------------------------------------------------------

- On May 16, 2023, Nasdaq notified TransCode it fails minimum $2.5M equity requirement with $(236,792) reported for Q1 2023.
- Company has 45 calendar days (until June 30, 2023) to submit a compliance plan to regain compliance.
- If Nasdaq accepts the plan, it may grant up to 180 additional days to meet the equity requirement.
- Separately, TransCode also faces a minimum bid price deficiency with deadline of June 7, 2023, adding delisting risk.
- TransCode does not meet alternative listing standards (market value of listed securities or net income).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923062121/0001104659-23-062121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923062121/tm2316168d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-062121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer